Publications by authors named "Mark Rupar"

Claim this Profile
S
Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN.
Edimara S Reis, Rebecca Buonpane, Hamza Celik, Caroline Marty, Angela Lei, Mark Rupar

Blood· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.
Holly K Koblish, Liangxing Wu, Liang-Chuan S Wang, Phillip C C Liu, Richard Wynn, Mark Rupar

Cancer Discov· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
Phillip C C Liu, Holly Koblish, Liangxing Wu, Kevin Bowman, Sharon Diamond, Mark Rupar

PLoS One· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Matthew C Stubbs, Timothy C Burn, Richard Sparks, Thomas Maduskuie, Sharon Diamond, Mark Rupar

Clin Cancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INCB040093 Is a Novel PI3K Inhibitor for the Treatment of B Cell Lymphoid Malignancies.
Niu Shin, Yun-Long Li, Song Mei, Kathy He Wang, Leslie Hall, Mark Rupar

J Pharmacol Exp Ther· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy.
Qiang Zhang, Yan Zhang, Sharon Diamond, Jason Boer, Jennifer J Harris, Mark Rupar

Drug Metab Dispos· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.
Paul Collier, Keyur Patel, Paul Waeltz, Mark Rupar, Rajyalakshmi Luthra

Genet Test Mol Biomarkers· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Alfonso Quintás-Cardama, Kris Vaddi, Phillip Liu, Taghi Manshouri, Jun Li, Mark Rupar

Blood· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
Priya Koppikar, Omar Abdel-Wahab, Cyrus Hedvat, Sachie Marubayashi, Jay Patel, Mark Rupar

Blood· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Xiangdong Liu, Niu Shin, Holly K Koblish, Gengjie Yang, Qian Wang, Mark Rupar

Blood· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphorylation State-Dependent High Throughput Screening of the c-Met Kinase.
Elham Behshad, Ronald M Klabe, Alexander Margulis, Mary Becker-Pasha, Mark J Rupar

Curr Chem Genomics· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput determination of mode of inhibition in lead identification and optimization.
Min Wei, Richard Wynn, Gregory Hollis, Boshan Liao, Alexander Margulis, Mark Rupar

J Biomol Screen· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.
Phillip C C Liu, Xiangdong Liu, Yanlong Li, Maryanne Covington, Richard Wynn, Mark Rupar

Cancer Biol Ther· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic.
Andrew P Combs, Wenyu Zhu, Matthew L Crawley, Brian Glass, Padmaja Polam, Mark Rupar

J Med Chem· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Binary toxins from Bacillus thuringiensis active against the western corn rootworm, Diabrotica virgifera virgifera LeConte.
James A Baum, Chi-Rei Chu, Mark Rupar, Gregory R Brown, William P Donovan

Appl Environ Microbiol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Purification of Her-2 extracellular domain and identification of its cleavage site.
Chao-Xing Yuan, Amy L Lasut, Richard Wynn, Nicola T Neff, Gregory F Hollis, Mark J Rupar

Protein Expr Purif· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters.
Reid M Huber, Kathleen Murphy, Bowman Miao, John R Link, Mark R Cunningham, Mark J Rupar

Gene· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of post-translational aspartyl beta-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia.
Joseph E Dinchuk, Richard J Focht, Jennifer A Kelley, Nancy L Henderson, Nina I Zolotarjova, Mark J Rupar

J Biol Chem· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis